Incomplete informed consent for psychotropic medications: The facility failed to ensure a resident or representative was fully informed before psychotropic meds were started or increased. Records for multiple residents showed consent forms that omitted dose, frequency, symptoms being treated, potential adverse effects, and alternative or non-pharmacological options for meds such as Alprazolam, Zoloft, Trazodone, Seroquel, Ativan, Cymbalta, Rexulti, Wellbutrin, Paroxetine, Lorazepam, Quetiapine, and Sertraline. The DON confirmed several consents were incomplete or missing.
Failure to Obtain Informed Consent for Psychotropic Medications: The facility administered psychotropic medications to multiple residents, including antidepressants and antipsychotics, without documented informed consent from the resident or representative. Records for residents with depression, dementia with agitation, and schizophrenia showed orders for medications such as mirtazapine, Paxil, Seroquel, duloxetine, risperidone, and Lexapro, but no evidence of advance discussion of risks, benefits, or alternative treatment options.
Incomplete psychotropic medication consents were found for two residents, with forms missing diagnosis selections, side effect information, and consent acknowledgements for meds such as alprazolam, divalproex, paroxetine, quetiapine, and mirtazapine. For another resident with depression and dementia, the record showed an order for Abilify but no evidence of a psychotropic consent signed by the resident or POA. The DON, Facility Administrator, nurse manager, and SDN confirmed the consent forms were incomplete or missing.
Failure to Obtain Psychotropic Medication Consent Before Initiation or Dose Increase: The DON confirmed that consent forms for psychotropic meds were missing from the records for three sampled residents, and the forms were not completed before the meds were started or increased. One resident was cognitively intact with depression and was receiving an antipsychotic and an antidepressant; another had severe cognitive impairment, dementia, agitation, and was receiving an antipsychotic and lorazepam; the third was cognitively intact with depression, PTSD, and was receiving an antidepressant and an antipsychotic. The facility later obtained telephone consent from POAs, but the required consent documentation was not in place before treatment began.
Failure to Obtain Informed Consent for Psychotropic Medications: The facility did not ensure informed consent was obtained before starting psychotropic medications for two residents. One resident with major depressive disorder was started on Seroquel without documented consent, and another resident with major depressive disorder, PTSD, irritability, and anger was started on Risperdal and Olanzapine without documented consent. The DON stated consent should be completed on admission for residents on psychotropics and when new psychotropic meds are initiated.
The facility failed to obtain consent before administering psychoactive meds to two residents. One resident received several doses of Mirtazapine before the POA was contacted about the consent form, and another resident received doses of an increased Abilify order before the consent was signed. The facility policy required signed consent before use and with dose changes, and the FA confirmed consent should have been obtained before administration.
Failure to Obtain Informed Consent for Psychotropic Medications: The facility did not inform residents or their representatives of the benefits, risks, and alternatives before starting psychotropic meds for multiple residents. Records showed antipsychotic, antidepressant, and antianxiety meds were given before psychoactive consent was completed, and the consents that were later signed did not consistently include benefits, alternatives, or specific target behaviors. The FA and ADON confirmed the consents were not completed at the correct time and were missing required information.
Failure to Document Psychotropic Medication Education: The facility did not document that residents or their representatives were informed about the risks, benefits, and alternate interventions for psychotropic medications when new orders were started or existing doses were changed. Two residents were affected: one with dementia, depression, anxiety, and insomnia who received multiple antidepressant and antipsychotic medications, and another with anxiety and major depression who received routine antipsychotic and antidepressant therapy. Staff interviews confirmed the missing documentation.
Incomplete informed consent for psychotropic medications was identified for several residents. Records showed psychotropic drugs were given for conditions such as anxiety, depression, dementia, and behavioral symptoms, but consent was often obtained after the meds had already started, and the forms did not include the doses or alternative treatment plans. An LPN confirmed the facility did not obtain consent before administration and did not secure new consent when doses were increased.
Failure to obtain informed consent for psychotropic medications. The DON confirmed that the facility did not educate or obtain consent before giving psychotropic meds to multiple residents. One resident had antidepressants ordered without any consent in the record, another had a psychotropic consent form that did not list the meds, risks, benefits, or non-pharmacological alternatives, and a cognitively intact resident receiving Rexulti had an incomplete consent form with no signatures or dates.
Self-audit
Pick a level of detail and, optionally, what to focus on — then generate a survey-ready checklist distilled from the most recent citations.
Beta · AI-generated — for reference only, not professional advice. Verify against current CMS guidance before relying on it. Assisto accepts no responsibility for how this checklist is used.
Citations used to create this checklist
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.